Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06686394 | RECRUITING | Breast Neoplasms

Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
Sponsor:

Merck Sharp & Dohme LLC

Brief Summary:

Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain breast cancers. The breast cancers being studied are HER2 positive unresectable locally advanced or metastatic (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment

Condition or disease

Breast Neoplasms

Breast Cancer

Intervention/treatment

Patritumab deruxtecan

Trastuzumab

Trastuzumab Biosimilar

Pertuzumab

Tucatinib

Phase

PHASE1

PHASE2

Detailed Description:

The following countries will be participating in the trial: Canada, United Kingdom, Israel, Japan, South Korea, and USA.

Study Type : INTERVENTIONAL
Estimated Enrollment : 81 participants
Masking : NONE
Primary Purpose : TREATMENT
Official Title : HERTHENA-Breast-01: A Phase 1b/2, Multicenter, Open-label, Dose-Finding Study to Evaluate the Safety and Antitumor Activity of Patritumab Deruxtecan in Participants With HER2 Positive Unresectable Locally Advanced Breast Cancer or Metastatic Breast Cancer
Actual Study Start Date : 2025-02-26
Estimated Primary Completion Date : 2029-09-10
Estimated Study Completion Date : 2029-09-10

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • The main inclusion criteria include but are not limited to the following
    • * Has histologically confirmed HER2+ locally advanced unresectable breast cancer or metastatic breast cancer
    • * Human immunodeficiency virus (HIV)-infected participants must have well-controlled HIV on antiretroviral therapy (ART)
    • * Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received HBV antiviral therapy for at least 4 weeks, and have undetectable hepatitis B virus (HBV) viral load before allocation
    • * Participants with history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable
    • * Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1 within 7 days before start of study intervention
    • Arm 1
      • * Has received at least a minimum of 2 and a maximum of 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
      • * Had disease progression on or after any previous trastuzumab deruxtecan (T-DXd) treatment
      • Arm 2
        • -Has received no more than 5 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting
        • Arm 3
          • -Has received and had disease progression from T-DXd treatment in any setting and a maximum of 3 prior lines of anti-HER2 therapy in the locally advanced or metastatic setting. T-DXd must be the most recent therapy received before enrollment.
          Exclusion Criteria
          • The main exclusion criteria include but are not limited to the following
            • * Uncontrolled or significant cardiovascular disease
            • * History of (noninfectious) pneumonitis/interstitial lung disease (ILD) that required steroids or has current pneumonitis/interstitial lung disease
            • * Has clinically severe respiratory compromise
            • * Has any history of or evidence of any current leptomeningeal disease
            • * Has clinically significant corneal disease
            • * Evidence of ongoing uncontrolled systemic bacterial, fungal, or viral infection
            • * HIV infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
            • * Known additional malignancy that is progressing or has required active treatment within the past 3 years
            • * Evidence of spinal cord compression or brain metastases
            • * Has an active infection requiring systemic therapy
            • * Concurrent active HBV and HCV infection
            • * Has had major surgical procedure (excluding placement of vascular access) less than 28 days
            • Arm 3 ONLY
            • - Has received prior treatment with tucatinib, lapatinib, or neratinib, or any investigational HER2-targeted tyrosine kinase inhibitors in the locally advanced or metastatic setting
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)

Location Details

NCT06686394

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, New Jersey

Rutgers Cancer Institute of New Jersey ( Site 0052)

New Brunswick, New Jersey, United States, 08901

RECRUITING

United States, South Carolina

Prisma Health - Upstate (ITOR)_Edenfield ( Site 0053)

Greenville, South Carolina, United States, 29605

RECRUITING

Israel,

Rambam Health Care Campus ( Site 0011)

Haifa, Israel, 3109601

RECRUITING

Israel,

Rabin Medical Center ( Site 0012)

Heels of a tip, Israel, 4941492

RECRUITING

Israel,

Sheba Medical Center ( Site 0010)

Ramat Gain, Israel, 5265601

RECRUITING

Korea, Republic of,

Seoul National University Hospital ( Site 0030)

Seoul, Korea, Republic of, 03080

RECRUITING

Korea, Republic of,

Asan Medical Center ( Site 0031)

Seoul, Korea, Republic of, 05505

RECRUITING

United Kingdom, London, City Of

St Bartholomew s Hospital ( Site 0040)

London, London, City Of, United Kingdom, Ec1a 7be